WD Pharmaceutical

Executive Summary

WD Pharmaceutical (WDP) is a preclinical-stage Chinese biotech company developing proprietary drug delivery systems to address unmet medical needs. Its core technologies include the UGi-Pump®, an upper gastrointestinal retention system, and the AcuSiS® platform, designed for pediatric and geriatric patients with swallowing difficulties. Initially targeting Parkinson's disease, WDP's pipeline also extends to cardiovascular and infectious disease indications. Founded in 2016 and headquartered in Shanghai, the company is privately held with an estimated 10-50 employees. Given its early stage, WDP's value hinges on successful preclinical validation and eventual clinical translation of its delivery platforms.

Upcoming Catalysts (preview)

• Q2 2026Preclinical data release for lead Parkinson's formulation60% success
• Q4 2026IND filing for lead candidate with UGi-Pump®40% success
• Q3 2026Partnership or licensing deal for AcuSiS® platform30% success